Spotlight on Japan
Back to Our Insights

Spotlight on Japan

As the world’s second-largest pharma and medtech market, Japan has historically been an innovation center for the industry. But amid an evolving healthcare landscape, this collection of articles and interviews looks at what opportunities and challenges executives at life-sciences companies need to address.
Article

Asia on the move: Five trends shaping the Asia biopharmaceutical market

– Enthusiasm for the biopharmaceutical sector in Asia has been flat, due in part to China’s market-access blockade, Japan’s spending controls, and deceleration in India and Southeast Asia. Recent changes have reignited interest in the region, with important implications for pharma executives.
Article

The evolving role of medical affairs in Asia−Pacific: Three imperatives for pharmacos

– Medical affairs is poised for a broader, more strategic role. However, leaders will need to ramp up new types of capabilities and talent to achieve this ambition.
Interview

What’s next for Japan’s pharma market

– The president of Merck in Japan discusses how healthcare players in the country can capitalize on early detection rates and use collaboration to drive innovation.
Interview

From semiconductors to life sciences: Building a global business out of Japan

– The president and CEO of JSR Corporation discusses the company’s plans to grow a global healthcare franchise building from his lessons in the semiconductor industry.
Article

The digital imperative for pharma companies in Japan

– Five facts showing that companies should invest in digital customer engagement in Japan.
Article

The medtech opportunity for Japanese companies

– A large-scale commitment to growth in healthcare technologies could be a key contributor to the Japanese economy.
Article

Elevating the impact of medical affairs in Japan

– Recent research sheds light on the value of the medical channel and what it takes to have a high-performing medical-affairs organization.